Total Payments
$202,917
2024 Payments
$164,257
Companies
11
Transactions
219
Payment Breakdown by Category
Consulting$91,120 (44.9%)
Other$90,591 (44.6%)
Travel$15,913 (7.8%)
Food & Beverage$5,283 (2.6%)
Education$10.17 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $91,120 | 27 | 44.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $90,591 | 21 | 44.6% |
| Travel and Lodging | $15,913 | 63 | 7.8% |
| Food and Beverage | $5,283 | 107 | 2.6% |
| Education | $10.17 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $55,735 | 44 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $49,899 | 45 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $44,104 | 56 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $43,528 | 49 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $9,411 | 16 | $0 (2024) |
| Indivior Inc. | $66.19 | 1 | $0 (2019) |
| ABBVIE INC. | $58.64 | 3 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $48.62 | 2 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $25.38 | 1 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.54 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $164,257 | 193 | E.R. Squibb & Sons, L.L.C. ($49,899) |
| 2023 | $38,593 | 25 | Teva Pharmaceuticals USA, Inc. ($21,044) |
| 2019 | $66.19 | 1 | Indivior Inc. ($66.19) |
All Payment Transactions
219 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $128.14 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $108.77 | General |
| 12/17/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $125.02 | General |
| Category: CNS | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,221.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,489.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,419.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,797.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,913.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,350.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,074.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $22.06 | General |
| 12/09/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: Central Nervous System | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,750.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/03/2024 | Alkermes, Inc. | — | Consulting Fee | Cash or cash equivalent | $808.00 | General |
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $755.15 | General |
| Category: Neuropsychiatry | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $410.16 | General |
| Category: Neuropsychiatry | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $322.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $250.47 | General |
| Category: Neuropsychiatry | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $91.41 | General |
| Category: Neuropsychiatry | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $78.63 | General |
| Category: Neuropsychiatry | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $44.53 | General |
| Category: Neuropsychiatry | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $28.70 | General |
| Category: Neuropsychiatry | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $4.36 | General |
| Category: Neuropsychiatry | ||||||
About Dr. Peter Weiden, MD
Dr. Peter Weiden, MD is a Psychiatry healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386754125.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Weiden, MD has received a total of $202,917 in payments from pharmaceutical and medical device companies, with $164,257 received in 2024. These payments were reported across 219 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($91,120).
Ad
Practice Information
- Specialty Psychiatry
- Location Chicago, IL
- Active Since 08/30/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1386754125
Products in Payments
- INGREZZA (Drug) $44,104
- UZEDY (Drug) $35,175
- COBENFY (Drug) $28,637
- ARISTADA (Drug) $14,025
- Austedo XR (Drug) $1,659
- PERSERIS (Drug) $66.19
- VRAYLAR (Drug) $58.64
- FANAPT (Drug) $48.62
- LYBALVI (Drug) $30.23
- INVEGA SUSTENNA (Drug) $25.38
- CAPLYTA (Drug) $20.54
- REXULTI (Drug) $19.87
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Chicago
Dr. Michelle Dees, Md, MD
Psychiatry — Payments: $523,545
Psychiatry $523,545
Mitchell Glaser, Md, MD
Psychiatry — Payments: $494,195
Psychiatry $494,195
Emil Coccaro, M.d, M.D
Psychiatry — Payments: $104,905
Psychiatry $104,905
Jon Grant
Psychiatry — Payments: $86,379
Psychiatry $86,379
Dr. Richard Baer, M.d, M.D
Psychiatry — Payments: $84,125
Psychiatry $84,125
K Ranga Krishnan, M.d, M.D
Psychiatry — Payments: $71,680
Psychiatry $71,680